BioCryst's Orladeyo Demonstrates Safety and Efficacy in Pediatric Hereditary Angioedema Trial
核心洞察
Interim analysis of APeX-P trial shows Orladeyo (berotralstat) oral granule formulation is safe and well-tolerated in children aged 2-12 years with hereditary angioedema (搜索).
Real-world evidence demonstrates significant reduction in HAE attack rates across patients with both C1-INH deficiency and normal C1-INH levels after Orladeyo initiation.
Patient-reported outcomes indicate high treatment satisfaction and reduced attack frequency and severity, with 54% of U.S. participants maintaining Orladeyo treatment for over one year.
BioCryst Pharmaceuticals has announced promising interim results from their APeX-P clinical trial, evaluating a pediatric-friendly oral granule formulation of Orladeyo (berotralstat) in young patients with hereditary angioedema (搜索) (HAE). The study, focusing on children aged 2 to under 12 years, marks a significant advancement in HAE management for pediatric populations.
Safety and Tolerability Profile
The interim analysis revealed a favorable safety profile for Orladeyo in pediatric patients, with no new safety signals identified during the trial. Adverse events were consistently similar across all age groups and weight categories, supporting the drug's potential as a suitable treatment option for young HAE patients.
Clinical Efficacy Findings
The trial demonstrated early and sustained reductions in monthly HAE attack rates among pediatric participants. This finding aligns with new real-world evidence showing statistically significant attack rate reductions in both adult and adolescent populations, specifically in patients with C1-INH deficiency and those with normal C1-INH levels and function.
Real-World Evidence and Patient Experience
Supporting data from real-world usage has provided valuable insights into Orladeyo's effectiveness. A comprehensive analysis of U.S. patients with HAE revealed:
- Mean patient age of 43.2 years
- Average of 13.4 years since diagnosis
- 54% of participants maintained Orladeyo treatment for at least one year
Patient-reported outcomes have been particularly encouraging, with most participants reporting decreased frequency and severity of HAE attacks after initiating Orladeyo treatment. This improvement was observed regardless of prior long-term prophylaxis (LTP) treatment status or duration of Orladeyo use.
Treatment Satisfaction and Patient Preferences
The study included an online discussion and survey component, exploring factors influencing patients' willingness to switch long-term prophylaxis treatments. Results indicated high satisfaction levels across varying attack frequencies and severities, suggesting Orladeyo's potential as a preferred long-term treatment option for HAE management.
These findings represent a significant step forward in expanding treatment options for pediatric HAE patients, offering a more convenient oral formulation while maintaining efficacy and safety standards essential for long-term disease management.